Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from melanoma cell lines 224 and BL transfected with siRNA-NRASQ61R

ABSTRACT: Transcriptional profiling for global characterization of gene expression alterations that resulted from treatment of melanoma cells with siRNA specifically targeting NRASQ61R

ORGANISM(S): Homo sapiens

PROVIDER: GSE12445 | GEO | 2008/08/31

SECONDARY ACCESSION(S): PRJNA113001

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

siRNA profiling of melanoma cell lines 224 and BL transfected with siRNA-NRASQ61R

Project description:Transcriptional profiling for global characterization of gene expression alterations that resulted from treatment of melanoma cells with siRNA specifically targeting NRASQ61R Experiment Overall Design: BL or 224 cells transfected with siRNA against either mutant NRASQ61R (siMut10 and siMut12) or scrambled control (siSC). Untransfected cells (T0) from Day 0 were used as the baseline control for cells transfected with both siMut and siSC

2008-10-25 | E-GEOD-12445 | biostudies-arrayexpress

siRNA profiling of melanoma cell lines 224 and BL transfected with siRNA-NRASQ61R

Project description: Not available

| S-ECPF-GEOD-12445 | biostudies-other

siRNA-mediated knockdown of MITF and PAX3 in metastatic melanoma cell lines

Project description:The transcription factors PAX3 and MITF are required for the development of the neural crest and melanocyte lineage, and both proteins play important roles in melanoma cell growth and survival. PAX3 transcriptionally activates MITF expression during neural crest development, but the relationship between these transcription factors during melanocyte development and in melanoma cells is currently poorly understood. This study aimed to further our understanding of the interaction between transcriptional networks controlled by PAX3 and MITF by assessing the effect of siRNA-mediated knockdown of PAX3 and MITF in metastatic melanoma cell lines. The goals of this study were to determine (i) if PAX3 is required for maintaining expression of MITF in melanoma and melanocyte cell lines; (ii) whether PAX3 and MITF independently, or redundantly, influence growth and survival in melanoma cell lines; and (iii) to investigate the respective roles of PAX3 and MITF expression in melanoma cell differentiation. Microarrays were used to measure global changes in transcript expression in response to siRNA-mediated knockdown of PAX3 or MITF compared to non-targeting controls in two metastatic melanoma cells lines. RNA was isolated from two different metastatic melanoma cell lines 30 hours after one of four different treaments: (i) transfection with siRNA targeting PAX3; or (ii) transfection with siRNA targeting MITF; or (iii) or transfection with siRNA targeting luciferase (non-targeting negative control); or (iv) treatment with media only (control). Therefore, eight samples were used for gene expression profiling by using GeneChip arrays, with one replicate per cell line per treatment.

2010-01-01 | E-GEOD-16249 | biostudies-arrayexpress

siRNA-mediated knockdown of MITF and PAX3 in metastatic melanoma cell lines

2010-01-02 | GSE16249 | GEO

siRNA induced silencing of CITED1 in HT144 human melanoma cells

Project description:To investigate the function of CITED1 in melanoma, its expression was transiently down regulated using CITED1-targeting siRNA. The HT144 melanoma cell line was chosen as it had a relatively high level of detectable CITED1 mRNA and protein expression. HT144 melanoma cells were transfected with 2 siRNAs targeting CITED1 (4 replicates each) and a negative control non-targeting siRNA (4 replicates). RNA was harvested at 48 h post-transfection.

2015-02-20 | E-GEOD-66113 | biostudies-arrayexpress

siRNA induced silencing of CITED1 in HT144 human melanoma cells

2015-02-20 | GSE66113 | GEO

RNA-Seq of human PDA cell lines transfected with control siRNA or Pdx1 siRNA

Project description:We compared the transcriptome of four human PDA lines: HPAF-II, Panc.05.04, Panc.8 and Panc.10.05 transfected with control siRNA or Pdx1 siRNA.

2019-12-06 | GSE90950 | GEO

human hTERT-RPE1 cell spheroid : Control siRNA transfected vs. YAP1 siRNA transfected

Project description:Transcriptional profiling of human hTERT-RPE1 cell spheroids comparing Control siRNA transfected hTERT-RPE1 cell spheroids with those transfected with YAP1 siRNA.

2015-02-01 | GSE54146 | GEO

Proteomic analysis of melanoma resistant cells transfected with siRNA targeting DDR2 or treated with DDR2 inhibitor or Dasatinib

Project description:Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In 70% of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.

2023-05-02 | PXD028292 | Pride

Expression data of human melanoma cell lines treated with siRNA targeting SR-BI or with the pharmacologic inhibitor BLT-1

Project description:Melanoma patients with high mRNA levels of the HDL receptor SR-BI (SCARB1) reveal poor survival outcome. The aim of the study was to evaluate the role of SR-BI in cancer progression. Therefore, SR-BI was targeted either by siRNA or by using the SR-BI specific lipid transfer inhibitor BLT-1. The SR-BI knockdown specifically revealed reduced protein glycosylation, STAT5 target gene expression and EMT pathway activation. Thus, SR-BI target genes reflect the metastatic phenotype in melanoma cells. We used the transcriptome analysis to compare SR-BI depletion to BLT-1 treatment (which specifically blocks SR-BI mediated lipid transfer) in human melanoma cells.

2018-01-02 | GSE96743 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data